Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Jul 9, 2009

Premium

Dicerna Pharmaceuticals announced that it has appointed David Madden as its chairman.

The company's previous chairman, Oxford Biosciences Partners partner Douglas Fambrough, remains on Dicerna's board.

Most recently, Madden was interim CEO of public pharmaceutical firm Adolor. Before that, he was co-CEO of Royalty Pharma. He holds a BS in electrical engineering from Union College and an MBA from Columbia University.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.